- Home
- ENTX vs KNDI Comparison
ENTX vs KNDI Comparison
Compare ENTX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- KNDI
- Stock Information
- Founded
- ENTX 2010
- KNDI 2002
- Country
- ENTX Israel
- KNDI China
- Employees
- ENTX N/A
- KNDI N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- KNDI Auto Manufacturing
- Sector
- ENTX Health Care
- KNDI Consumer Discretionary
- Exchange
- ENTX Nasdaq
- KNDI Nasdaq
- Market Cap
- ENTX 104.0M
- KNDI 96.3M
- IPO Year
- ENTX 2018
- KNDI N/A
- Fundamental
- Price
- ENTX N/A
- KNDI $1.13
- Analyst Decision
- ENTX Strong Buy
- KNDI
- Analyst Count
- ENTX 1
- KNDI 0
- Target Price
- ENTX $10.00
- KNDI N/A
- AVG Volume (30 Days)
- ENTX 32.3K
- KNDI 97.2K
- Earning Date
- ENTX 08-08-2025
- KNDI 08-15-2025
- Dividend Yield
- ENTX N/A
- KNDI N/A
- EPS Growth
- ENTX N/A
- KNDI N/A
- EPS
- ENTX N/A
- KNDI N/A
- Revenue
- ENTX $223,000.00
- KNDI $127,569,613.00
- Revenue This Year
- ENTX N/A
- KNDI N/A
- Revenue Next Year
- ENTX N/A
- KNDI N/A
- P/E Ratio
- ENTX N/A
- KNDI N/A
- Revenue Growth
- ENTX N/A
- KNDI 3.21
- 52 Week Low
- ENTX $1.41
- KNDI $0.89
- 52 Week High
- ENTX $2.79
- KNDI $2.12
- Technical
- Relative Strength Index (RSI)
- ENTX 45.61
- KNDI 48.38
- Support Level
- ENTX $1.84
- KNDI $1.06
- Resistance Level
- ENTX $2.02
- KNDI $1.16
- Average True Range (ATR)
- ENTX 0.13
- KNDI 0.07
- MACD
- ENTX -0.01
- KNDI 0.00
- Stochastic Oscillator
- ENTX 23.53
- KNDI 42.86
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.